Assessment of neutralizing antibody response as a correlate of protection against symptomatic SARS-CoV-2 infections after administration of two doses of the CoronaVac inactivated COVID-19 vaccine: A phase III randomized controlled trial
The results highlight the value of neutralizing antibody response as a correlate of protection, which can be used to inform future vaccine development and implementation. Further studies of immune correlates of protection for other vaccines are warranted.
Authors
- Wey Wen Lim (ORCID: https://orcid.org/0000-0001-8514-2048)
- Qianqian Xin (ORCID: https://orcid.org/0000-0002-4342-7974)
- Hongjie Yu (ORCID: https://orcid.org/0000-0002-6335-5648)
- Benjamin J. Cowling (ORCID: https://orcid.org/0000-0002-6297-7154)
- Weining Meng
- Xinhua Chen (ORCID: https://orcid.org/0000-0002-3944-3816)
- Xing Meng (ORCID: https://orcid.org/0009-0005-6242-2000)
- Qianhui Wu
- Dimas Tadeu Covasa
Institutions
- Fudan University (CN)
- Instituto Butantan (BR)
- Sinovac Biotech (CN)
- Shanghai Public Health Clinical Center (CN)
- Ministry of Education (KR)
- University of Hong Kong (HK)
Publication Details
- Journal
- Journal of Infection
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1016/j.jinf.2024.106315
- Citations
- 2
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.78
Funders
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
- China National Funds for Distinguished Young Scientists
- National Science Fund for Distinguished Young Scholars